List of Excipients in Branded Drug DETROL LA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	ETHYLCELLULOSE
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	FD&C BLUE NO. 2
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	FERRIC OXIDE YELLOW
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	GELATIN
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	HYPROMELLOSE
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	MEDIUM-CHAIN TRIGLYCERIDES

Detrol LA Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Detrol LA is an extended-release capsule containing tolterodine tartrate, an antimuscarinic used to treat overactive bladder. Its commercial differentiation comes from multiparticulate extended-release technology rather than from the active ingredient. The principal opportunity for generic and reformulated products is to reproduce the release profile with alternative polymer systems, simplify manufacturing, reduce cost, or create differentiated dosage forms.

The original product’s core formulation strategy uses drug-loaded beads with polymeric release control. That design creates several development barriers: matching dissolution across multiple pH conditions, controlling bead coating thickness, maintaining capsule content uniformity, and demonstrating bioequivalence against the reference product.

What is Detrol LA and how does its formulation work?

Detrol LA contains tolterodine tartrate in 2 mg and 4 mg extended-release capsules. The product is administered once daily, unlike immediate-release Detrol tablets, which are generally administered twice daily. The formulation releases tolterodine over an extended period through coated multiparticulates contained inside a hard gelatin capsule.

Detrol LA formulation profile

Attribute	Detrol LA
Active ingredient	Tolterodine tartrate
Pharmacologic class	Muscarinic receptor antagonist
Dosage form	Extended-release hard gelatin capsule
Strengths	2 mg and 4 mg
Route	Oral
Primary indication	Overactive bladder with urinary urgency, frequency and urge incontinence
Release technology	Multiparticulate, polymer-controlled release
Reference sponsor	Pharmacia, now within the Pfizer legacy portfolio
FDA application	NDA 021228
Generic pathway	Abbreviated New Drug Application, subject to FDA bioequivalence requirements

The label identifies inactive materials associated with the drug-containing beads, release-controlling coating and capsule shell. The formulation includes pharmaceutical excipients such as sugar spheres, hypromellose, ethylcellulose and capsule-shell materials, although suppliers and grades may vary by manufacturing site and approved product version. [1]

Why multiparticulates matter

Multiparticulate systems divide the dose among many small drug-loaded units. Compared with a single monolithic matrix tablet, this approach can provide:

• More consistent gastrointestinal distribution
• Lower sensitivity to localized tablet defects
• Greater control over release through coating thickness
• Flexibility in combining immediate-release and extended-release fractions
• Potentially lower risk of sharp concentration peaks

For a generic manufacturer, the key challenge is not simply selecting an extended-release polymer. The applicant must reproduce the reference product’s in vitro and in vivo performance closely enough to satisfy FDA requirements.

What excipients protect the Detrol LA release profile?

The most commercially important excipients are the release-controlling polymers and the bead-core materials. They determine drug loading, coating uniformity, water penetration, diffusion rate and mechanical robustness.

Core excipient functions

Excipient category	Likely function in the product	Commercial relevance
Sugar spheres	Inert bead substrate	Supports drug layering and consistent particle size
Corn starch or starch-containing materials	Bead composition and processing support	Affects density, friability and coating performance
Hypromellose	Binder or film-forming polymer	Supports drug layering and may influence release
Ethylcellulose	Water-insoluble release-control polymer	Primary tool for slowing tolterodine release
Plasticizers or lipidic processing aids	Improve coating flexibility and processability	Can reduce cracking and improve coating integrity
Gelatin	Hard capsule shell	Controls shell compatibility and patient acceptability
Titanium dioxide and colorants	Capsule appearance and identification	Relevant to supply continuity and product differentiation

The exact grade of each excipient is material. Hypromellose viscosity, ethylcellulose particle size, polymer substitution and plasticizer content can materially change dissolution. A generic formulation that uses the same nominal excipient may still fail to match the reference profile if the grade, coating weight gain or process conditions differ.

Excipient patents versus formulation know-how

The strongest competitive protection in an extended-release generic is often manufacturing know-how rather than a single excipient patent. Important technical variables include:

• Drug layering onto the starter bead
• Binder concentration and spray rate
• Bed temperature during coating
• Polymer solids concentration
• Coating weight gain
• Plasticizer ratio
• Cure temperature and time
• Capsule fill weight
• Storage humidity
• Packaging moisture barrier

These variables can produce patentable process claims, but they also create trade-secret value. A competitor may use different polymers and still obtain approval if it demonstrates bioequivalence and acceptable dissolution.

What generic products compete with Detrol LA?

Tolterodine extended-release capsules are small-molecule generic products. Biosimilar competition does not apply because tolterodine is a chemically synthesized active pharmaceutical ingredient, not a biologic.

Competitive product categories

Product category	Competitive position
Tolterodine immediate-release tablets	Lower-cost alternative with more frequent dosing
Generic tolterodine ER capsules	Direct substitutable competition
Detrol LA	Reference extended-release product
Oxybutynin ER	Competing antimuscarinic with a different active ingredient
Solifenacin	Competing once-daily antimuscarinic
Darifenacin	Competing antimuscarinic
Fesoterodine	Related antimuscarinic prodrug
Mirabegron	Beta-3 adrenergic agonist, non-antimuscarinic mechanism
Vibegron	Beta-3 adrenergic agonist

The most direct commercial opportunity is a low-cost generic tolterodine ER capsule. A differentiated reformulation would need a clear advantage, such as lower manufacturing cost, improved capsule stability, reduced excipient burden, or a delivery system that supports a new regulatory pathway.

When did Detrol LA lose exclusivity?

Detrol LA’s original regulatory and patent exclusivity periods have expired, allowing generic development. FDA-approved generic tolterodine extended-release products have entered the U.S. market through the ANDA pathway.

Exclusivity timeline

Milestone	Approximate timing
Detrol immediate-release approval	1990s
Detrol LA FDA approval	2000
Initial reference-product market exclusivity	Expired
Historical U.S. patent protection	Expired
Generic tolterodine ER development	Active after loss of exclusivity
Current competitive basis	Price, supply reliability, reimbursement and formulation execution

The commercial barrier is therefore regulatory and technical rather than a continuing basic patent monopoly. A current product-specific patent and litigation determination requires review of the latest FDA Orange Book and federal court records. The Orange Book remains the controlling source for active listed patents and pediatric exclusivity associated with an approved reference product. [2]

What Orange Book and Paragraph IV issues affect tolterodine ER?

Tolterodine ER applicants can use the ANDA pathway if they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A Paragraph IV certification is generally relevant when an applicant asserts that an Orange Book-listed patent is invalid, unenforceable or not infringed.

For a mature product such as Detrol LA, the practical significance of Paragraph IV litigation is lower than during the initial generic wave because the principal historical exclusivity periods have expired. The remaining issues may include:

• Late-listed formulation patents
• Manufacturing-process patents
• Litigation over patent-term calculations
• 30-month stays triggered by timely patent litigation
• First-filer or limited generic exclusivity rights
• Paragraph III certifications tied to future expiration dates

The absence of a current listed patent should not be inferred solely from the age of the product. Patent status can change through corrections, delistings, pediatric extensions or regulatory updates. [2]

What excipient strategies can reduce generic development risk?

A generic manufacturer has three main formulation routes.

1. Reference-matching bead system

This approach uses a drug-layered bead and ethylcellulose or similar polymer coating to replicate the reference dissolution profile.

Advantages include:

• Lower formulation risk
• Familiar multiparticulate manufacturing
• Strong alignment with the reference product
• Straightforward capsule filling

The disadvantages are the need for highly controlled coating equipment and extensive process characterization.

2. Alternative polymer coating

A manufacturer can use a different release-controlling polymer or polymer blend, including aqueous ethylcellulose dispersions, ammonio methacrylate copolymers or other approved film-forming systems.

This route may lower solvent-handling costs and improve coating throughput. It also creates greater bioequivalence risk because polymer permeability, pore formation and film aging can change the release curve.

3. Matrix-based capsule or tablet

A matrix formulation can reduce manufacturing complexity by eliminating bead layering. Hydrophilic matrices based on high-viscosity hypromellose or other polymers may be commercially attractive.

The main risks are:

• Failure to reproduce the reference multiparticulate release profile
• Greater sensitivity to food and gastrointestinal transit
• Dose dumping under alcohol exposure
• Higher variability at the terminal phase of release
• More difficult control of the 2 mg and 4 mg strength relationship

The matrix route is more suitable for a 505(b)(2) reformulation or a product with a clinically differentiated claim than for a conventional ANDA seeking a close reference match.

What formulation patents could support a reformulated tolterodine product?

Potentially protectable subject matter includes:

• Specific polymer combinations
• Defined bead-size distributions
• Coating weight-gain ranges
• Controlled-release profiles
• Capsule compositions
• Multiparticulate blends
• Reduced food-effect formulations
• Alcohol-resistant release systems
• Manufacturing conditions that produce a defined dissolution profile
• New salts, polymorphs or solid-state forms
• Combination products with another overactive-bladder therapy

A formulation patent must provide more than a routine substitution of one approved excipient for another. Stronger claims would link the excipient system to a measurable technical result, such as a defined dissolution profile, reduced pharmacokinetic variability or improved resistance to dose dumping.

What commercial opportunities exist in Detrol LA excipients?

Excipient suppliers

Suppliers can target manufacturers developing tolterodine ER products with:

• High-purity ethylcellulose
• Aqueous polymer dispersions
• Controlled-viscosity hypromellose
• Narrow-particle-size sugar spheres
• Functional coating additives
• Low-peroxide excipients
• Capsule shells with improved moisture performance

The opportunity is recurring supply rather than a large-volume active ingredient market. Tolterodine ER is a mature generic market, so price, regulatory documentation and supply continuity are likely to matter more than premium functionality alone.

Contract development and manufacturing

CDMOs with fluid-bed coating, drug-layering and multiparticulate expertise can offer:

• Formulation screening
• Scale-up of bead coating
• Dissolution method development
• Stability studies
• Exhibit-batch manufacturing
• ANDA support
• Commercial capsule filling

The most defensible capability is process reproducibility at commercial scale. Laboratory release data do not reliably predict coating performance at production scale without robust process controls.

Finished-dose reformulation

A reformulated product could target:

• Lower capsule size
• Reduced capsule-shell colorants
• Improved moisture stability
• Lower excipient load
• Sprinkle administration, if supported by data and labeling
• Alternative packaging for hot and humid markets
• Fixed-dose combinations
• Extended-release products with differentiated pharmacokinetics

Each route would carry a different FDA strategy. A conventional generic requires sameness and bioequivalence. A clinically differentiated reformulation may require a 505(b)(2) application, supporting clinical or pharmacokinetic evidence and potentially new patent protection. [3]

How strong is the Detrol LA patent estate?

The original product estate is commercially weak as a barrier to ordinary generic entry because the principal patent and exclusivity periods have expired. The remaining value is more likely to lie in formulation know-how, process controls, regulatory files and supply-chain execution.

Patent-strength assessment

Estate component	Current strategic value
Basic tolterodine composition claims	Low after expiry
Original extended-release claims	Low after expiry
Active Orange Book blocking patents	Must be verified in the current listing
New polymer formulation claims	Potentially material for a reformulation
Manufacturing-process claims	Moderate if difficult to design around
Trade secrets	Moderate to high for scale-up know-how
Regulatory exclusivity	Expired for the original product
Biosimilar barriers	Not applicable

A new applicant should separate freedom-to-operate analysis for tolterodine tartrate, the dosage form, excipient combination, coating process and proposed labeling. Patent risk may be low at the active-ingredient level while remaining meaningful for a specific delivery system.

What generic launch scenarios exist for Detrol LA?

Low-cost conventional generic

This is the most likely commercial model. The sponsor matches the reference product, obtains ANDA approval and competes through reimbursement access, manufacturing cost and supply reliability.

Premium generic with supply advantages

A manufacturer can differentiate through:

• Dual-source excipients
• Domestic or regional manufacturing
• Lower back-order risk
• Improved packaging
• Reliable 2 mg and 4 mg availability

This strategy is commercially relevant in mature markets where pharmacy substitution is common and product shortages influence formulary behavior.

505(b)(2) delivery-system product

A new multiparticulate or matrix system could target improved food compatibility, alcohol resistance or administration flexibility. It would require a stronger clinical and regulatory case but could support new formulation patents.

Geographic expansion

Markets with continued use of antimuscarinic therapy may support tolterodine ER products where generic penetration remains incomplete. Regulatory requirements, trademark restrictions, local excipient acceptability and pharmacopoeial standards differ by jurisdiction. The core technical opportunity is transferable, but the commercial case depends on local reimbursement and competing products.

What FDA regulatory status applies to Detrol LA?

Detrol LA is an FDA-approved prescription drug. Generic versions are regulated through the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA evaluates the finished dosage form, not only the active pharmaceutical ingredient.

Key development requirements include:

• Assay and content uniformity
• Multiparticulate or matrix characterization
• Comparative dissolution
• Stability under ICH conditions
• Pharmacokinetic bioequivalence
• Food-effect assessment where applicable
• Alcohol dose-dumping evaluation for extended-release products
• Capsule-shell compatibility
• Control of degradation products
• Manufacturing-process validation

FDA’s product-specific guidance and ANDA requirements should govern study design and formulation selection. [3,4]

Key Takeaways

• Detrol LA is a tolterodine tartrate extended-release capsule based on multiparticulate release technology.
• The most important excipients are ethylcellulose, hypromellose, sugar spheres and capsule-shell materials.
• The primary generic challenge is matching the reference dissolution and pharmacokinetic profile, not obtaining the active ingredient.
• Biosimilar risk is irrelevant because tolterodine is a small-molecule drug.
• The original patent and exclusivity barriers have expired, making conventional generic entry commercially feasible.
• Excipient suppliers can compete through polymer performance, regulatory support and supply reliability.
• CDMOs with fluid-bed coating and multiparticulate expertise have the strongest technical positioning.
• A differentiated reformulation may support new patents, but it would require a more demanding 505(b)(2) strategy.
• Current Orange Book listings and litigation records should control any final patent or Paragraph IV conclusion.

FAQs

Is Detrol LA an extended-release formulation?

Yes. Detrol LA is a once-daily extended-release capsule containing tolterodine tartrate in a multiparticulate delivery system.

Which polymer is most important for a tolterodine ER generic?

Ethylcellulose is a key candidate for controlling water penetration and drug diffusion, while hypromellose may support drug layering, film formation or release modulation. The commercial result depends on polymer grade, coating weight and process conditions.

Can a manufacturer replace ethylcellulose with another polymer?

Yes, provided the resulting product satisfies FDA quality and bioequivalence requirements. A polymer substitution can materially change dissolution and may increase development risk.

Is a tolterodine ER product eligible for a 505(b)(2) application?

A conventional equivalent generally uses the ANDA pathway. A product with a materially different formulation, dosage form, administration method or clinical profile may be eligible for a 505(b)(2) strategy if the statutory and evidentiary requirements are met.

What is the best commercial entry strategy for Detrol LA?

For most manufacturers, a reference-matched generic capsule is the lowest-risk route. A differentiated polymer system or new delivery format offers greater patent and pricing potential but carries higher formulation, clinical and regulatory risk.

References

1. U.S. Food and Drug Administration. (2000). Detrol LA (tolterodine tartrate) extended-release capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (n.d.). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.